Bone Marrow Microvessel Area
| Patients/Status and Control Subjects (no.) . | Microvessel Area as mm2 × 10−2 Mean ± SD (range) . | Cellular Area as mm2 × 10−2 Mean ± SD (range) . |
|---|---|---|
| MM | ||
| Active (26) | 0.50 ± 0.23 (0.14-1.01)* | 11.2 ± 0.7 (9.3-12.2) |
| Diagnosis (10) | 0.34 ± 0.15 (0.14-0.62)* | 11.2 ± 0.6 (10.3-12.2) |
| Relapse (10) | 0.49 ± 0.17 (0.19-0.74)* | 11.0 ± 0.8 (9.3-12) |
| Progression (6) | 0.59 ± 0.32 (0.51-1.01)* | 11.4 ± 0.7 (10-12.1) |
| Nonactive (18) | 0.11 ± 0.02 (0.08-0.19) | 10.4 ± 0.7 (9.4-12) |
| Response (11) | 0.11 ± 0.03 (0.08-0.19) | 10.3 ± 0.7 (9.4-11.5) |
| Plateau (7) | 0.11 ± 0.01 (0.08-0.15) | 10.5 ± 0.8 (9.5-12) |
| MGUS (20) | 0.11 ± 0.02 (0.08-0.15) | 10.6 ± 0.7 (9.4-11.8) |
| Control subjects (12) | 0.08 ± 0.01 (0.07-0.09) | 10.3 ± 0.5 (9.1-10.5) |
| Patients/Status and Control Subjects (no.) . | Microvessel Area as mm2 × 10−2 Mean ± SD (range) . | Cellular Area as mm2 × 10−2 Mean ± SD (range) . |
|---|---|---|
| MM | ||
| Active (26) | 0.50 ± 0.23 (0.14-1.01)* | 11.2 ± 0.7 (9.3-12.2) |
| Diagnosis (10) | 0.34 ± 0.15 (0.14-0.62)* | 11.2 ± 0.6 (10.3-12.2) |
| Relapse (10) | 0.49 ± 0.17 (0.19-0.74)* | 11.0 ± 0.8 (9.3-12) |
| Progression (6) | 0.59 ± 0.32 (0.51-1.01)* | 11.4 ± 0.7 (10-12.1) |
| Nonactive (18) | 0.11 ± 0.02 (0.08-0.19) | 10.4 ± 0.7 (9.4-12) |
| Response (11) | 0.11 ± 0.03 (0.08-0.19) | 10.3 ± 0.7 (9.4-11.5) |
| Plateau (7) | 0.11 ± 0.01 (0.08-0.15) | 10.5 ± 0.8 (9.5-12) |
| MGUS (20) | 0.11 ± 0.02 (0.08-0.15) | 10.6 ± 0.7 (9.4-11.8) |
| Control subjects (12) | 0.08 ± 0.01 (0.07-0.09) | 10.3 ± 0.5 (9.1-10.5) |
P < .01 or lower versus nonactive myeloma as a group and subgroups (analysis of variance by Fisher and Kruskal-Wallis test followed by paired Duncan [t], Bonferroni [t], and Wilcoxon tests).